Acute Myelogenous Lymphoma (AML)

First (CR1)/Second (CR2) Remission

BMT330
Phase II Very Low Dose Total Body Irradiation in Combination with Total Lymphoid Irradiation and anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-MHCT

PI: Muffy
Pending

BMT302
Phase II Ibrutinib Maintenance After Reduced-Intensity Conditioning & Allogeneic HCT in Acute Leukemia

PI: Rezvani
Stanford

BMT322
Phase III FLT3 Inhibitor Gilteritinib Maintenance Therapy After Allogeneic Transplant in FLT3/ITD AML

PI: Muffy
BMT CTN

Advanced Disease

FLT3 Mutation

BMT326
Phase III MAHCT w/ T Cell Depleted Graft w/ Infusion of Conventional and Regulatory T Cells PI: Meyer NIH

PI: Meyer
NIH

Matched Related Donor

First (CR1) or Higher Remission

Haplo

BMT326
Phase III Haploidentical HSCT & ATIR101 or Post-Transplant Cyclophosphamide in Hematologic Malignancy

PI: Johnson
Pending